SCHEMBL6840653

SCHEMBL6840653

CCOc1cc(O)c2c(=O)o[c]cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.42
RET P07949 1/20 0.42
KDR P35968 1/20 0.42
ADORA3 P0DMS8 2/20 0.40
QPCT Q16769 1/20 0.39
ACE2 Q9BYF1 1/20 0.38
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ANTXR2 P58335 1/20 0.35
NPC1 O15118 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
SLC5A1 P13866 1/20 0.34
SLC5A2 P31639 1/20 0.34
ALDH2 P05091 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840673 0.84 PTGS1 (0.43) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL6344640 0.69 AKR1C3 (0.47) EGFRRETKDRADORA3QPCT
SCHEMBL5540550 0.66 CYP1A2 (0.45) ALDH1A1MAPTKDM4ENPC1CA12
SCHEMBL6348904 0.65 EGFR (0.42) EGFRRETKDRADORA3QPCT
SCHEMBL533344 0.63 CA12 (0.53) ALDH1A1KDM4ENPC1RAB9ACA12
SCHEMBL2493501 0.62 LTA4H (0.52) ALDH1A1MAPTSLC5A1SLC5A2CA12
SCHEMBL70827 0.62 LTA4H (0.52) ALDH1A1MAPTSLC5A1SLC5A2CA12
SCHEMBL28069517 0.61 ADORA3 (0.55) EGFRRETKDRADORA3QPCT
SCHEMBL29196803 0.61 SLC5A1 (0.50) ALDH1A1MAPTMAPK1KDM4ENPC1
SCHEMBL971905 0.60 LTA4H (0.45) ADORA3ALDH1A1MAPTKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024015-A1 Tumor radiosensitization and /or chemopotentiation using isocoumarin derivatives GLBC LLC 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024015-A1 Tumor radiosensitization and /or chemopotentiation using isocoumarin derivatives HCCS, IDH2, IDH3A EGFR 3349/4885RET 3626/4885KDR 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.